354 related articles for article (PubMed ID: 36276933)
1. Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma.
Cong T; Luo Y; Liu Y; Yang C; Yang H; Li Y; Li J; Li X
Front Genet; 2022; 13():1000997. PubMed ID: 36276933
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
4. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
5. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
6. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification.
Chen Z; Du D; Li J; Zhang W; Shao J
Transl Cancer Res; 2024 Mar; 13(3):1268-1289. PubMed ID: 38617510
[TBL] [Abstract][Full Text] [Related]
7. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
8. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
11. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
12. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Immune Cell Infiltration in Hepatocellular Carcinoma.
Li Y; Song K; Zheng W
J Oncol; 2023; 2023():9557690. PubMed ID: 36891559
[TBL] [Abstract][Full Text] [Related]
13. Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma.
Zhang Q; Huang Y; Xia Y; Liu Y; Gan J
Clin Exp Med; 2023 Oct; 23(6):2051-2064. PubMed ID: 36153416
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
[No Abstract] [Full Text] [Related]
15. A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma.
Zhang Q; Ma L; Zhou H; Zhou Y; Liu S; Li Q
Front Oncol; 2022; 12():1040736. PubMed ID: 36324575
[TBL] [Abstract][Full Text] [Related]
16. A novel cuproptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma.
Yang F; Jiang S; Liu Y; Zhang T; Zhu C; Zhang L; Sang X; Lu X; Wei J; Deng K; Zheng Y; Xu Y
Heliyon; 2022 Nov; 8(11):e11768. PubMed ID: 36468143
[TBL] [Abstract][Full Text] [Related]
17. Prognosis, Immune Microenvironment Infiltration and Immunotherapy Response in Clear Cell Renal Cell Carcinoma Based on Cuproptosis-related Immune Checkpoint Gene Signature.
Liu G; Li F; Ge Y; Shi Y; Ren F; Zhu L
J Cancer; 2023; 14(17):3335-3350. PubMed ID: 37928426
[No Abstract] [Full Text] [Related]
18. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
20. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
